InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.03
(
-0.12%
)
Bitcoin
64,077.50
(
0.12%
)
Post# of 251721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

acgood

Send PM Follow Ignore
Followers 18
Posts 1093
Boards Moderated 0
Alias Born 05/12/2007

acgood

Re: iwfal post# 148299

Thursday, 09/06/2012 11:27:04 PM

Thursday, September 06, 2012 11:27:04 PM

Post# of 251721
The SNTA trial is not blinded. The company sure had the data in hand for weeks last time as they talked the stock from 4 to 8 w/ wall street analysts in June. No reason to believe anything different is happening this time.

Two key notes for me from Stifel
- final PFS data for phase 3 already pushed back from 1h2014 to 2014 (and didn't reiterate 2014 NDA)
- didn't show/discuss the subgroup data - are they reversing and considering phase 3 in all adeno? mentioned OS benefit in all adeno specifically this time

Opinions and comments may have been previously posted @BioDueDiligence, at www.biotechduediligence.com, or disseminated to Chimera Research Group subscribers.

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up